

Malaria Drug Discovery Portfolio and Collaborators

- Malaria Signal Peptide Peptidase as a new antimalarial drug target (in collaboration with NIBR-Basel and Doron Greenbaum of the University of Pennsylvania)
- Spiro-Indolone scaffold lead optimization
- Quinazoline derivatives - Inhibition of antifolate drug resistant Plasmodium (in collaboration with KEMRI/Wellcome Trust Kilifi)
- Hit-to-Lead follow-up of cellular screens (in collaboration with GNF and Novartis Natural Products Unit)

Abbreviations:

- GCGH: Grand Challenges in Global Health 11 project: 'Drugs for latent TB'
- Imperial College (funded by Bill and Melinda Gates Foundation, Wellcome Trust)
- NIBR: Novartis Institute for Biomedical Research
- GNF: Genomics Institute of the Novartis Foundation
- NIH: National Institute of Health